Clinic of Gastroenterology and Gastrointestinal Oncology, University Medical Center Göttingen, Göttingen, Germany.
Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen, Göttingen, Germany.
Exp Clin Endocrinol Diabetes. 2020 Sep;128(9):582-595. doi: 10.1055/a-1084-3888. Epub 2020 Jan 20.
The human urea transporter SLC14A1 (HUT11/UT-B) has been suggested as a marker for the adipogenic differentiation of bone cells with a relevance for bone diseases. We investigated the function of SLC14A1 in different cells models from bone environment. SLC14A1 expression and cytokine production was investigated in bone cells obtained from patients with osteoporosis. Gene and protein expression of SLC14A1 was studied during adipogenic or osteogenic differentiation of human mesenchymal progenitor cells (hMSCs) and of the single-cell-derived hMSC line (SCP-1), as well as in osteoclasts and chondrocytes. Localization was determined by histochemical methods and functionality by urea transport experiments. Expression of SLC14A1 mRNA was lower in cells from patients with osteoporosis that produced high levels of cytokines. Accordingly, when adding a combination of cytokines to SCP-1 SLC14A1 mRNA expression decreased. SLC14A1 mRNA expression decreased after both osteogenic and more pronounced adipogenic stimulation of hMSCs and SCP-1 cells. The highest SLC14A1 expression was determined in undifferentiated cells, lowest in chondrocytes and osteoclasts. Downregulation of SLC14A1 by siRNA resulted in an increased expression of interleukin-6 and interleukin-1 beta as well as adipogenic markers. Urea influx through SLC14A1 increased expression of osteogenic markers, adipogenic markers were suppressed. SLC14A1 protein was localized in the cell membrane and the cytoplasm. Summarizing, the SLC14A1 urea transporter affects early differentiation of hMSCs by diminishing osteogenesis or by favoring adipogenesis, depending on its expression level. Therefore, SLC14A1 is not unequivocally an adipogenic marker in bone. Our findings suggest an involvement of SLC14A1 in bone metabolism and inflammatory processes and disease-dependent influences on its expression.
人类尿素转运蛋白 SLC14A1(HUT11/UT-B)被认为是骨细胞成脂分化的标志物,与骨疾病有关。我们研究了 SLC14A1 在骨环境中不同细胞模型中的功能。在骨质疏松症患者获得的骨细胞中,研究了 SLC14A1 的表达和细胞因子的产生。研究了人间充质祖细胞(hMSC)和成骨细胞和成脂细胞分化过程中 SLC14A1 的基因和蛋白表达,以及破骨细胞和软骨细胞中的表达。通过组织化学方法确定定位,通过尿素转运实验确定功能。SLC14A1 mRNA 的表达在产生高水平细胞因子的骨质疏松症患者的细胞中较低。因此,当向 SCP-1 添加细胞因子组合时,SLC14A1 mRNA 的表达降低。hMSC 和 SCP-1 细胞进行成骨和成脂刺激后,SLC14A1 mRNA 的表达均降低。未分化细胞中 SLC14A1 表达最高,软骨细胞和破骨细胞中最低。siRNA 下调 SLC14A1 导致白细胞介素-6 和白细胞介素-1β以及成脂标志物的表达增加。通过 SLC14A1 的尿素内流增加了成骨标志物的表达,抑制了成脂标志物的表达。SLC14A1 蛋白定位于细胞膜和细胞质。总之,SLC14A1 尿素转运蛋白通过减少成骨或促进成脂,根据其表达水平,影响 hMSC 的早期分化。因此,SLC14A1 在骨中不是成脂标志物。我们的研究结果表明 SLC14A1 参与骨代谢和炎症过程,并且其表达受到疾病的影响。